BCS class I (dispersible tablet): selection of reference product [Regulatives / Guidelines]

posted by yuva – 2023-08-01 13:23 (355 d 00:08 ago) – Posting: # 23690
Views: 2,056

Dear All,

A BCS class I molecule is formulated as an immediate release tablet and is intended to be dispersed in a glass of water at the time of administration. The dispersed tablet will not be completely dissolved at the time of patient intake. Kindly do not conclude it as an effervescent tablet and there is no reference product available in market with similar features to be selected as a comparator for this ANDA filing.

Having said that, will it be acceptable to select an "oral solution" from the market as a reference and opt for "Solution based waiver" approach?
Will the regulatory agencies accept this idea? If yes, what can be the maximum volume (250mL is the best to consider) and maximum duration of time to consider for generating in-vitro data to establish sameness between Test and Reference?

Thanks in advance

Complete thread:

UA Flag
 Admin contact
23,112 posts in 4,858 threads, 1,644 registered users;
61 visitors (0 registered, 61 guests [including 12 identified bots]).
Forum time: 13:32 CEST (Europe/Vienna)

It’s always fun to have your models validated,
but is way more fun to have them trashed.
Finding out you are completely wrong
is a great part of science.    G. Randall Gladstone

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz